Get started
ChromaDex CorporationChromaDex CorporationChromaDex Corporation

ChromaDex Corporation

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

CDXC trade ideas

Reduced recovery time in mild-to-moderate COVID-19 patientsNew Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients New Phase 3 study results show added nutritional protocol reduces recovery time in mild-to-moderate COVID-19 patients The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish standard of care not only reduced recovery time but improved liver health and decreased levels of inflammatory markers. finance.yahoo.com
NASDAQ:CDXC
by AlenCiken
CDXC: Small Float Biopharma with BIG Potential $20After basing for many years, CDXC is showing signs of awakening. Stocks are being accumulated but not aggressively. It's one of few bio stocks with insider buying at the current price. The co is likely on track doing $200 mil revenue in 2 or 3 years, 10X of the 200 mil revenue = 2 bil market cap, with about 62 mil shares O/S. Potentially huge valuation creation. Backed by smart biopharma investors with a tiny float (56% controlled by 20 investors). Their product is patented with an 80% gross margin. It is however a stock for patient investors, not fly by the night type of stocks. It is in my Long Term portfolio.
NASDAQ:CDXCLong
by Jonas99
CDXC 4.8: Small Float Biotech backed by Li Ka Shing In this market where SPEC trades at billions with NO revenue, I like CDXC though I may be early. Yes it's not TSLA, yes Value does not work in this market but With a tiny market cap of 290 mil and revenue growth at 40% (still early-stage market), I am betting with Li Ka Shing, one of the richest and other top 20 institutions including Blackrock who collectively owns 55% of the stock. Short interest is small at 7%. The better story is that the stock has been basing for a long time, and technicals are improving. I don't want to wait for breakout then buy as by then I would be paying too much a premium. So good enough for me with the IMPROVING technicals and a largely positive trend, and a real growth story. investors.chromadex.com asia.nikkei.com Top Shareholders Top 25 shareholders own 54.62% of the company Ownership Name Shares Current Value Change % Portfolio % 10.49% Ka-shing Li 6,500,937 $31.4m 0% no data 10.29% Hoi Shuen Chau 6,377,783 $30.8m 0% no data 4.53% BlackRock, Inc. 2,804,544 $13.5m -0.81% no data 3.97% The Vanguard Group, Inc. 2,461,485 $11.9m 9.03% no data 3.8% Li Ka Shing (Global) Foundation, Endowment Arm 2,353,139 $11.4m 0% 3.25% 3.11% Phillip and Patricia Frost Philanthropic Foundation, Inc, Endowment Arm 1,929,542 $9.3m 0% 42.91% 2.76%
NASDAQ:CDXCLong
by Jonas99
2
CDXC Chromadex Corp Upside TaregtsChromadex Corp. is a nutraceutical company. The firm engages in acquiring, developing and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Los Angeles, CA.
NASDAQ:CDXC
by DEXWireNews
1
Chromadex Corp On breakout alert $cdxcPossible breakout imminent from a year congestion channel Weekly MACd and Histogram bullish move Moving averages converging Volume spiking Chromadex Corp. is a nutraceutical company. The firm engages in acquiring, developing and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Los Angeles, CA.
NASDAQ:CDXC
by Bullishcharts
$CDXC ChromaDex Corp A Breakout Above $5We have been watching $CDXC for quite awhile and the stock is on verge of a breakout. A move above $5 would be new 52-week highs and get the momentum players into the stock. We are going in at $5.01 and not much of a stop will be needed. For those that use a money stop, 5% to 10% risk is sufficient. About ChromaDex: ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company. As always, trade with caution and use protective stops. Good luck to all!
NASDAQ:CDXC
by InsiderFinancial